189 related articles for article (PubMed ID: 8635123)
1. Serum transforming growth factor alpha level as a marker of hepatocellular carcinoma complicating cirrhosis.
Tomiya T; Fujiwara K
Cancer; 1996 Mar; 77(6):1056-60. PubMed ID: 8635123
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of transforming growth factor alpha and vascular endothelial growth factor in diagnosis of hepatocellular carcinoma.
El-Sherif WT; Makhlouf NA; El-Gendi SS; Hassan HI; Herdan OM
Egypt J Immunol; 2012; 19(2):53-65. PubMed ID: 23885407
[TBL] [Abstract][Full Text] [Related]
3. Plasma transforming growth factor-beta 1 in patients with hepatocellular carcinoma. Comparison with chronic liver diseases.
Shirai Y; Kawata S; Tamura S; Ito N; Tsushima H; Takaishi K; Kiso S; Matsuzawa Y
Cancer; 1994 May; 73(9):2275-9. PubMed ID: 7513247
[TBL] [Abstract][Full Text] [Related]
4. Transforming growth factor beta1 and soluble Fas serum levels in hepatocellular carcinoma.
Sacco R; Leuci D; Tortorella C; Fiore G; Marinosci F; Schiraldi O; Antonaci S
Cytokine; 2000 Jun; 12(6):811-4. PubMed ID: 10843770
[TBL] [Abstract][Full Text] [Related]
5. Association of serum level of growth differentiation factor 15 with liver cirrhosis and hepatocellular carcinoma.
Liu X; Chi X; Gong Q; Gao L; Niu Y; Chi X; Cheng M; Si Y; Wang M; Zhong J; Niu J; Yang W
PLoS One; 2015; 10(5):e0127518. PubMed ID: 25996938
[TBL] [Abstract][Full Text] [Related]
6. Low utility of plasma Nociceptin/orphanin FQ in the diagnosis of hepatocellular carcinoma.
Spadaro A; Ajello A; Luigiano C; Morace C; Resta ML; Berlinghieri G; Campo S; Scisca C; Alibrandi A; D'Arrigo G; Alessi N; Ferrau O; Freni MA
World J Gastroenterol; 2006 Aug; 12(29):4716-20. PubMed ID: 16937445
[TBL] [Abstract][Full Text] [Related]
7. Transforming growth factor-β1 gene expression in hepatocellular carcinoma: a preliminary report.
Farid IM; Hamza IM; El-Abd DM; Mohyi AM; AbdulLatif MM; Aref AT; Hamza DM
Arab J Gastroenterol; 2014; 15(3-4):142-7. PubMed ID: 25475758
[TBL] [Abstract][Full Text] [Related]
8. Serological biomarkers of hepatocellular carcinoma in Egyptian patients.
El-Tayeh SF; Hussein TD; El-Houseini ME; Amer MA; El-Sherbini M; Elshemey WM
Dis Markers; 2012; 32(4):255-63. PubMed ID: 22430192
[TBL] [Abstract][Full Text] [Related]
9. Clinical evaluation of urinary transforming growth factor-beta1 and serum alpha-fetoprotein as tumour markers of hepatocellular carcinoma.
Tsai JF; Jeng JE; Chuang LY; Yang ML; Ho MS; Chang WY; Hsieh MY; Lin ZY; Tsai JH
Br J Cancer; 1997; 75(10):1460-6. PubMed ID: 9166938
[TBL] [Abstract][Full Text] [Related]
10. Transforming growth factor-alpha and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma.
Harada K; Shiota G; Kawasaki H
Liver; 1999 Aug; 19(4):318-25. PubMed ID: 10459631
[TBL] [Abstract][Full Text] [Related]
11. The Bcl-2 and TGF-beta1 levels in patients with chronic hepatitis C, liver cirrhosis and hepatocellular carcinoma.
Ali MA; Koura BA; el-Mashad N; Zaghloul MH
Egypt J Immunol; 2004; 11(1):83-90. PubMed ID: 15724390
[TBL] [Abstract][Full Text] [Related]
12. A simple diagnostic index comprising epithelial membrane antigen and fibronectin for hepatocellular carcinoma.
Attallah AM; El-Far M; Abdel Malak CA; Farid K; Omran MM; Yahya RS; Saad EA; Albannan MS; Attallah AA; El Basuni MA; Ali IS; Abed SB; El Naggar MA
Ann Hepatol; 2015; 14(6):869-80. PubMed ID: 26436359
[TBL] [Abstract][Full Text] [Related]
13. Urinary transforming growth factor α and serum α-fetoprotein as tumor markers of hepatocellular carcinoma.
Jeng JE; Tsai MF; Tsai HR; Chuang LY; Lin ZY; Hsieh MY; Chen SC; Chuang WL; Wang LY; Yu ML; Dai CY; Tsai JF
Tumour Biol; 2014 Apr; 35(4):3689-98. PubMed ID: 24375326
[TBL] [Abstract][Full Text] [Related]
14. Serum 90K/MAC-2BP glycoprotein in patients with liver cirrhosis and hepatocellular carcinoma: a comparison with alpha-fetoprotein.
Iacovazzi PA; Trisolini A; Barletta D; Elba S; Manghisi OG; Correale M
Clin Chem Lab Med; 2001 Oct; 39(10):961-5. PubMed ID: 11758611
[TBL] [Abstract][Full Text] [Related]
15. Transforming growth factor-beta1 as a useful serologic marker of small hepatocellular carcinoma.
Song BC; Chung YH; Kim JA; Choi WB; Suh DD; Pyo SI; Shin JW; Lee HC; Lee YS; Suh DJ
Cancer; 2002 Jan; 94(1):175-80. PubMed ID: 11815974
[TBL] [Abstract][Full Text] [Related]
16. Elevated serum visfatin levels are associated with poor prognosis of hepatocellular carcinoma.
Sun Y; Zhu S; Wu Z; Huang Y; Liu C; Tang S; Wei L
Oncotarget; 2017 Apr; 8(14):23427-23435. PubMed ID: 28178643
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the Clinical Utility of Glypican 3 as a Serum Marker for the Diagnosis of Hepatocellular Carcinoma.
Jia X; Gao Y; Zhai D; Liu J; Cai J; Wang Y; Jing L; Du Z
Technol Cancer Res Treat; 2016 Dec; 15(6):780-786. PubMed ID: 26370140
[TBL] [Abstract][Full Text] [Related]
18. Latent transforming growth factor-beta binding protein-1 in circulating plasma as a novel biomarker for early detection of hepatocellular carcinoma.
Cao B; Yang L; Rong W; Feng L; Han N; Zhang K; Cheng S; Wu J; Xiao T; Gao Y
Int J Clin Exp Pathol; 2015; 8(12):16046-54. PubMed ID: 26884881
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers.
Tangkijvanich P; Chanmee T; Komtong S; Mahachai V; Wisedopas N; Pothacharoen P; Kongtawelert P
J Gastroenterol Hepatol; 2010 Jan; 25(1):129-37. PubMed ID: 19793164
[TBL] [Abstract][Full Text] [Related]
20. [Clinical significance of transiently elevated serum AFP level in developing hepatocellular carcinoma in HBsAg positive-liver cirrhosis].
Lee HY; Jung JH; Kang YS; Kim YS; Moon HS; Park KO; Lee YS; Kim SM; Seo SW; Lee SW; Kim SH; Lee BS; Kim NJ
Korean J Gastroenterol; 2004 Apr; 43(4):252-9. PubMed ID: 15100489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
